Anti-CTLA-4 monoclonal antibodies such as ipilimumab bind CTLA-4 to shut down inhibitory signals, enabling CTLs to persist with their cytotoxic activities against cancer cells (53). The gene discussed is CTLA4; the disease is cancer.